Dose Escalation
Dose Escalation — A study design where the compound dose is progressively increased to determine safety thresholds and optimal dosing ranges for peptide compounds.
What Is Dose Escalation?
Dose escalation is the systematic increase of peptide dose across sequential cohorts in Phase I clinical trials to determine safety, tolerability, maximum tolerated dose (MTD), and preliminary PK. Each cohort receives a higher dose only after the previous cohort completes safety monitoring.
Escalation Designs
- 3+3: Traditional design. 3 subjects per dose level. Expand to 6 if DLT observed
- Accelerated titration: Single subject per cohort until first toxicity, then switch to 3+3
- Modified Fibonacci: Dose increments decrease with ascending doses (100%, 67%, 50%, 33%)
- Allometric starting dose: Human starting dose derived from animal NOAEL using species scaling
Frequently Asked Questions
What is Dose Escalation?
A study design where the compound dose is progressively increased to determine safety thresholds and optimal dosing ranges for peptide compounds.
Why is Dose Escalation important in peptide research?
Dose Escalation is a fundamental concept in research as it relates to peptide science. It directly influences experimental design, compound characterization, and the reliability of research outcomes across biochemistry and molecular biology disciplines.
Authority Sources
- Dose Escalation on Wikipedia
- Search Dose Escalation on PubChem (NIH)
- Research articles on ScienceDirect